Ezzelle J, Rodriguez-Chavez I R, Darden J M, Stirewalt M, Kunwar N, Hitchcock R, Walter T, D'Souza M P
PPD Inc., 929 North Front Street, Wilmington, NC 28401-3331, United States.
J Pharm Biomed Anal. 2008 Jan 7;46(1):18-29. doi: 10.1016/j.jpba.2007.10.010. Epub 2007 Oct 13.
A set of Good Clinical Laboratory Practice (GCLP) standards that embraces both the research and clinical aspects of GLP were developed utilizing a variety of collected regulatory and guidance material. We describe eleven core elements that constitute the GCLP standards with the objective of filling a gap for laboratory guidance, based on IND sponsor requirements, for conducting laboratory testing using specimens from human clinical trials. These GCLP standards provide guidance on implementing GLP requirements that are critical for laboratory operations, such as performance of protocol-mandated safety assays, peripheral blood mononuclear cell processing and immunological or endpoint assays from biological interventions on IND-registered clinical trials. The expectation is that compliance with the GCLP standards, monitored annually by external audits, will allow research and development laboratories to maintain data integrity and to provide immunogenicity, safety, and product efficacy data that is repeatable, reliable, auditable and that can be easily reconstructed in a research setting.
利用各种收集到的法规和指南材料,制定了一套涵盖GLP研究和临床方面的良好临床实验室规范(GCLP)标准。我们描述了构成GCLP标准的11个核心要素,目的是根据IND申办者的要求,填补实验室指南方面的空白,以便使用来自人类临床试验的标本进行实验室检测。这些GCLP标准为实施对实验室操作至关重要的GLP要求提供了指导,例如方案规定的安全性检测、外周血单个核细胞处理以及对IND注册临床试验中的生物干预进行免疫或终点检测。预期通过每年由外部审计进行监测,遵守GCLP标准将使研发实验室能够保持数据完整性,并提供可重复、可靠、可审计且在研究环境中易于重建的免疫原性、安全性和产品功效数据。